Earnings ·
MaxCyte reported second quarter 2026 financial results with total revenue of $7.3 million, a 15% decrease from the…
MXCTMaxcyte, Inc.
MaxCyte reported second quarter 2026 financial results with total revenue of $7.3 million, a 15% decrease from the prior year period. Core business revenue was $6.5 million, down 21%, while Strategic Platform License (SPL) Program-related revenue rose to $0.8 million from $0.3 million. The company posted a net loss of $8.9 million compared to $12.4 million in the same period last year, with operating expenses reduced to $15.8 million from $21.2 million. Gross profit was $5.6 million with a 77% gross margin. Management reiterated full-year 2026 revenue guidance of $30 million to $32 million and expects to end the year with at least $130.5 million in cash, excluding further share repurchases. The company has repurchased approximately $5.5 million of common stock under its authorized program and announced a strategic multi-platform technology license partnership with Genentech following the quarter-end.